Condensed Consolidated Statement of Cash Flows Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2021		Sep. 30, 2020
Cash flows - operation activities:
Net loss	$ (126)		$ (3,502)
Non-cash items -
Share-based plans expense	677		165
Treasury shares issued for 401(k) contribution	951
Depreciation and amortization	1,610		1,668
Investment/asset impairment charges, net	72		317
Customer financing valuation adjustments	(3)		12
Gain on dispositions, net	(283)		(200)
Other charges and credits, net	(82)		912
Changes in assets and liabilities -
Accounts receivable	(280)		125
Unbilled receivables	(2,010)		56
Advances and progress billings	781		428
Inventories	(508)		9,653
Other current assets	279		319
Accounts payable	(3,565)		(3,303)
Accrued liabilities	(3,168)		967
Income taxes receivable, payable and deferred	1,011		(2,404)
Other long-term liabilities	(168)		(149)
Pension and other postretirement plans	(731)		(556)
Customer financing, net	170		108
Other	225		289
Net cash used by operating activities	(4,132)		(14,401)
Cash flows - investing activities:
Property, plant and equipment additions	(758)		(1,038)
Property, plant and equipment reductions	385		275
Acquisitions, net of cash acquired	(6)
Contributions to investments	(27,902)		(25,846)
Proceeds from investments	35,664		9,772
Other	6		14
Net cash provided/(used) by investing activities	7,389		(16,823)
Cash flows - financing activities:
New borrowings	9,822		42,362
Debt repayments	(11,049)		(8,792)
Stock options exercised	36		31
Employee taxes on certain share-based payment arrangements	(47)		(169)
Dividends paid			(1,158)
Net cash (used)/provided by financing activities	(1,238)		32,274
Effect of exchange rate changes on cash and cash equivalents, including restricted	(34)		26
Net increase in cash & cash equivalents, including restricted	1,985		1,076
Cash & cash equivalents, including restricted, at beginning of year	7,835		9,571
Cash & cash equivalents, including restricted, at end of period	9,820		10,647
Restricted Cash and Cash Equivalents	(56)	[1]	(83)
Cash and cash equivalents at end of period	$ 9,764		$ 10,564

[1] Reflects amounts restricted in support of our property sales, workers’ compensation programs, employee benefit programs, and insurance premiums.Allowance for losses on available for sale debt instruments are assessed quarterly. All instruments are considered investment grade and, as such, we have not recognized an allowance for credit losses as of September 30, 2021.